摘要
CXCL8 是一种与多种神经退行性疾病相关(如阿尔茨海默病与中风)的低分子量中性粒细胞趋化因子。有报道称CXCL8在 HIV-1感染病人的血清、血浆和大脑中表达增加,这表明其与HIV相关的神经性炎症密切相关。因为趋化因子在引起中枢神经系统(CNS)免疫反应时十分关键,而CXCL8作为在大脑中被首次发现的一种趋化因子而显得十分重要。 由HIV-1或病毒相关蛋白激活的星形胶质细胞和小胶质细胞促使脑微环境中趋化因子的生成。因此, CXCL8通过G蛋白偶联受体CXCR1和CXCR2发挥对靶细胞的作用。中性粒细胞是CXCL8的主要靶细胞;本文旨在讨论应对HIV-1感染时,CXCL8在神经元和神经胶质细胞中的产生、信号传导和调节。本文主要关注于CXCL8调节过程中的HIV-1分泌蛋白反转录激活因子、包膜糖蛋白、负调控因子和病毒蛋白r。我们讨论了CXCL8对神经退行性疾病的双重作用和对CNS的神经保护作用。因此,通过CXCR1 /CXCR2为基础的治疗方法,以CXCL8为靶点选择性地激动或拮抗受体,可以选择性促进神经保护作用和增强抗炎效果,这对于中枢神经系统神经炎症包括HIV相关的神经认知障碍的治疗有着重要的临床意义。
关键词: 趋化因子,CXCL8,CXCR1/CXCR2,HIV-1,神经退行性疾病,神经保护作用。
图形摘要
Current Drug Targets
Title:CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Volume: 17 Issue: 1
Author(s): Manmeet K. Mamik and Anuja Ghorpade
Affiliation:
关键词: 趋化因子,CXCL8,CXCR1/CXCR2,HIV-1,神经退行性疾病,神经保护作用。
摘要: Chemokine CXCL8 is a low molecular weight neutrophil chemoattractant implicated in various neurodegenerative disorders including Alzheimer's disease and stroke. Increased expression of CXCL8 has been reported in serum, plasma and brain of human immunodeficiency virus (HIV)-1 infected individuals with neurocognitive impairment, indicating its role in neuroinflammation associated with HIV-1 infection of the brain. Since chemokines are critical in eliciting immune responses in the central nervous system (CNS), CXCL8 is of particular importance for being one of the first chemokines described in the brain. Activation of astrocytes and microglia by HIV-1 and virus associated proteins results in production of this chemokine in the brain microenvironment. Consequently, CXCL8 exerts its effect on target cells via Gprotein coupled receptors CXCR1 and CXCR2. Neutrophils are the main target cells for CXCL8; however, microglia and neurons also express CXCR1/CXCR2 and therefore are important targets for CXCL8-mediated crosstalk. The objective of this review is to focus on CXCL8 production, signaling and regulation in neuronal and glial cells in response to HIV-1 infection. We highlight the role of HIV-1 secreted proteins such as trans-activator of transcription, envelope glycoprotein, negative regulatory factor and viral protein r in the regulation of CXCL8. We discuss dual role of CXCL8 in neurodegeneration as well as neuroprotection in the CNS. Thus, targeting CXCL8 through the development of CXCR1/CXCR2-based therapeutic strategies to either selectively agonize or antagonize receptors may be able to selectively promote neuroprotective and anti-inflammatory outcomes, leading to significant clinical applications in many neuroinflammatory CNS diseases, including HIV-associated neurocognitive disorders.
Export Options
About this article
Cite this article as:
Manmeet K. Mamik and Anuja Ghorpade , CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders, Current Drug Targets 2016; 17 (1) . https://dx.doi.org/10.2174/1389450116666150626124544
DOI https://dx.doi.org/10.2174/1389450116666150626124544 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Nitric Oxide Induced Damage and Preventive Effect of Curcumin and Quercetin on Buffalo Brain Cystatin
Current Proteomics Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
CNS & Neurological Disorders - Drug Targets Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Copper Status Abnormalities and How to Measure Them in Neurodegenerative Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Curcuminoids in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research Neuropeptides in Alzheimer’s Disease: An Update
Current Alzheimer Research Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Noncoding RNAs and Intracerebral Hemorrhage
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Mitochondria as a Pharmacological Target: A Clue for Efficacy and a Reason for Toxicity (Executive Guest Editor: Nadezda Apostolova)]
Current Pharmaceutical Design Reacting to Stress: Radical Cellular Pathways for Novel Drug Development
Current Neurovascular Research The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators
Current Pharmaceutical Design Clinical Neurophysiology of Brain Plasticity in Aging Brain
Current Pharmaceutical Design Relevance of Nutritional Antioxidants in Metabolic Syndrome, Ageing and Cancer: Potential for Therapeutic Targeting
Infectious Disorders - Drug Targets Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued)